Pharmaceutical

ICTCAR-028 by Innovative Cellular Therapeutics for Hematological Tumor: Likelihood of Approval

ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.

Jul 6, 2024 - 04:00
ICTCAR-028 is under clinical development by Innovative Cellular Therapeutics and currently in Phase III for Hematological Tumor.
Read the original article

Tags:

Previous Article

CAN-3110 by Candel Therapeutics for High-Grade Glioma: Likelihood of Approval

Next Article

LP-184 by Starlight Therapeutics for Non-Small Cell Lung Cancer: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: 3 trends to watch in biotech in 2024

STAT+: 3 trends to watch in biotech in 2024

Dec 21, 2023

Opinion: After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies

Opinion: After living with sickle cell disease for 39 y...

Dec 9, 2023

STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients

STAT+: GSK is replacing its popular Flovent inhaler wit...

Jan 6, 2024